Archive: SRPT Stock Analysis

Formerly AVI BioPharma $AVII

This page contains an archive of all publicly published Sarepta Therapeutics, eteplirsen, and Duchenne Muscular Dystrophy (DMD) articles with a focused on SRPT stock trading and potential.

Sarepta SRPT BiotechDueDiligence Homepage
Archive of eteplirsen patient-focused stories and articles

Stock Analysis and Reporting

Here is a collection of viewpoints, summaries, and opinions on eteplirsen, Sarepta Therapeutics' $SRPT therapy in development for Duchenne Muscular Dystrophy. Note that my links are not an endorsement of any particular opinion or perspective:

• September 2010 "Rodman Rambles: Promising Biotechs" (TheStreet - Adam Feuerstein)
• June 2011 "AVI Biopharma CEO Chris Garabedian Seeks to Avoid Quick Flip, Build Enduring Drug Company" (Xconomy) - an interview with Sarepta CEO Chris Garabedian shortly after taking over the company, by Luke Timmerman.
• April 2012 "Genetic Fix From AVI Biopharma Builds Key Muscle Function Protein" (The Street - Adam Feuerstein)
• April 2012 "Bioteech Mailbag: AVII" (TheStreet)
• July 2012 "Sarepta may have found treatment breakthrough for Muscular Dystrophy" (TheStreet - Adam Feuerstein)
• August 2012 "Sarepta makes strides in DMD (Chimera Research Group - Jason Chew)
• August 2012 "SRPT Second Patient Doing Well on Muscular Dystrophy Drug Trial"  (TheStreet - Adam Feuerstein)
• August 2012 "SRPT: Trade Strategy #1" (Chimera Research Group)
• August 2012 "Why I believe $SRPT (Eteplirsen) will be approved w/ positive 48 week data despite small N" (Matt Rosen)
• September 2012 "Sarepta Therapeutics: A high octane options trade" (TheStreet contributor Tony Pelz)
• September 2012 "Sarepta Outperformed Biotechs In August Due To Muscular Dystrophy Drug" (Forbes - Matthew Herper)
• September 2012 "SRPT: Trade strategy #2" (Chimera Research Group)
• September 2012 SRPT chart and technical analysis (Joe Gantoss)
• September 2012 "Sarepta Therapeutics Looks Highly Undervalued" (Seeking Alpha - Sean Anderson)
• September 2012 "Sarepta: approaching major catalyst" (Chimera Research Group)
• September 2012 SRPT comments regarding safety profile (@themicrokid)
• September 2012 "A new reason to be bullish about Sarepta Therapeutics" (TheStreet contributor Nathan Sadeghi-Nejad)
• September 2012 "SRPT: Trade strategy #3" (Chimera Research Group)
• October 2012 "Can Sarepta Keep Soaring?" (CEO appearance on CNBC Mad Money with Jim Cramer)
• October 2012 "Sarepta's next step: early FDA approval" (The Street)
• October 2012 "In a first, n experimental drug may help boys with muscular dystrophy" (Forbes - Matthew Herper)
• October 2012 "Sarepta drug helps boys with Duchenne to walk" (Xconomy - Luke Timmerman)
• October 2012 "Sarepta shares still have upside" (The Street contributor Nathan Sadeghi-Nejad)
• October 2012 "Sarepta fails to report meaningful dystrophin expression data" (Dirk Haussecker)
• October 2012 "My Thoughts on Sarepta" (Aafia Chaudhry)
• October 2012 "The SRPT bear case" (TheStreet)
• October 2012 - discussion about Summer Street conference call re SRPT (Apeering)
• October 2012 "Lazard analyst note is generating buzz" (The Street)
• October 2012 "Sarepta Part I: The Possibility Of An Accelerated Approval Of Eteplirsen" (SeekingAlpha - LifeSci Advisors)
• October 2012 "Sarepta Part II: Commercial Potential Of Eteplirsen In The Next Hot Market For Orphan Drug" (LifeSci Adv)
• October 2012 "Sarepta’s Eteplirsen and FDA’s “Breakthrough Therapy” Designation: A Perfect Fit?" (Elsevier)
• October 2012 "How to hedge profits in Sarepta" (The Street - Tony Pelz)
• October 2012 "SRPT technical analysis" (Joe Gantoss)
• November 2012 "Sarepta Therapeutics Still Looks Ridiculously Undervalued" (SeekingAlpha - Sean Anderson)
• November 2012 "Sarepta likely to face uphill battle if it seeks accelerated approval for eteplirsen" (BioPharm Insight)
• November 2012 "Buzz on Sarepta's Eteplirsen From London Duchenne Meeting" (TheStreet - Adam Feuerstein)

Continue to read the most recent SRPT stock analysis pieces (dated 2013)